Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 3
3(75.0%)
N/A
1(25.0%)
4Total
Phase 3(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT06299007Completed

Awareness of Iron Status Evaluation in UGIB

Role: lead

NCT06165328Recruiting

The Comparison Between Computed Tomography and Colonoscope in Detecting Colorectal Tumors in Patients With FIT+

Role: lead

NCT05550402Not ApplicableRecruiting

Role of Parasympathetic Activity in Mild to Severe Asthma With Fixed Airway Obstruction (PARASMA Study)

Role: lead

NCT04215848Phase 3Completed

As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period

Role: lead

NCT04454385Completed

The Correlations of FeNO, Blood Eosinophils and Lung Function in Well-controlled Asthma

Role: lead

NCT04277078Completed

Predicting Intubation of Patients Hospitalised for Acutely Attacked Asthma

Role: lead

NCT02806141Phase 3Terminated

Aerosolized Plus Intravenous vs. Intravenous Colistin for VAP Due to Pandrugs-resistant A. Baumannii in Neonates

Role: lead

NCT02725242Phase 3Completed

Efficacy of Once-daily Budesonide/Formoterol Turbuhaler 4.5/160 µg in Step Down Asthma

Role: lead

All 8 trials loaded